These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

362 related items for PubMed ID: 8748388

  • 1. Future directions in anxiolytic pharmacotherapy.
    Kunovac JL, Stahl SM.
    Psychiatr Clin North Am; 1995 Dec; 18(4):895-909. PubMed ID: 8748388
    [Abstract] [Full Text] [Related]

  • 2. [Treatment of generalized anxiety: new pharmacologic approaches].
    Boulenger JP.
    Encephale; 1995 Dec; 21(6):459-66. PubMed ID: 8674471
    [Abstract] [Full Text] [Related]

  • 3. Benzodiazepines for the treatment of panic disorder and generalized anxiety disorder: clinical issues and future directions.
    Bradwejn J.
    Can J Psychiatry; 1993 Nov; 38 Suppl 4():S109-13. PubMed ID: 7905780
    [Abstract] [Full Text] [Related]

  • 4. GABAA receptors as targets for novel anxiolytic drugs.
    Rupprecht R, Eser D, Zwanzger P, Möller HJ.
    World J Biol Psychiatry; 2006 Nov; 7(4):231-7. PubMed ID: 17071543
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. New molecular targets for antianxiety interventions.
    Gorman JM.
    J Clin Psychiatry; 2003 Nov; 64 Suppl 3():28-35. PubMed ID: 12662131
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs.
    Palucha A, Pilc A.
    Pharmacol Ther; 2007 Jul; 115(1):116-47. PubMed ID: 17582504
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H, Namba K.
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [New anxiolytic drugs: methodological issues].
    Ginestet D, Corruble E.
    Encephale; 1993 Dec; 19(6):627-37. PubMed ID: 12404782
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [A new group of anxiolytic drugs with a mechanism of action different from that of benzodiazepine derivatives].
    Kostowski W, Płaźnik A.
    Pol Tyg Lek; 1993 Dec; 43(51-52):1647-9, 1683. PubMed ID: 2908340
    [No Abstract] [Full Text] [Related]

  • 16. Neurobiologic basis of anxiety and its treatment.
    Salzman C, Miyawaki EK, le Bars P, Kerrihard TN.
    Harv Rev Psychiatry; 1993 Dec; 1(4):197-206. PubMed ID: 9384849
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs.
    Gaetani S, Dipasquale P, Romano A, Righetti L, Cassano T, Piomelli D, Cuomo V.
    Int Rev Neurobiol; 2009 Dec; 85():57-72. PubMed ID: 19607961
    [Abstract] [Full Text] [Related]

  • 20. Abecarnil for the treatment of generalized anxiety disorder: a placebo-controlled comparison of two dosage ranges of abecarnil and buspirone.
    Pollack MH, Worthington JJ, Manfro GG, Otto MW, Zucker BG.
    J Clin Psychiatry; 1997 Dec; 58 Suppl 11():19-23. PubMed ID: 9363044
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.